Erratum: AT1 receptor blockade alters metabolic, functional and structural proteins after reperfused myocardial infarction: Detection using proteomics (Molecular and Cellular Biochemistry (184) 10.1023/B:MCBI.0000041860.97991.7a);AT1receptor blockade alters metabolic, functional and structural proteins after reperfused myocardial infarction: Detection using proteomics

Molecular and Cellular Biochemistry

Volumn 263, Issue 1, 2004, Pages 179-188

  Jugdutt, Bodh I ^a   Sawicki, Grzegorz ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Angiotensin II receptor antagonists; Metabolic enzymes; Myocardial infarction; Proteins; Proteomics; Reperfusion

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; CONTRACTILE PROTEIN; CREATINE KINASE; DRUG VEHICLE; ENZYME PRECURSOR; IRBESARTAN; ISOCITRATE DEHYDROGENASE (NAD); ISOENZYME; MYOSIN LIGHT CHAIN; PROTON TRANSPORTING ADENOSINE TRIPHOSPHATE SYNTHASE; STRUCTURAL PROTEIN; VALSARTAN; ANGIOTENSIN RECEPTOR ANTAGONIST; BIPHENYL DERIVATIVE; DRUG DERIVATIVE; ISOCITRATE DEHYDROGENASE; PROTEIN; PROTON TRANSPORTING ADENOSINE TRIPHOSPHATASE; TETRAZOLE DERIVATIVE; VALINE;

ALPHA CHAIN; AMINO ACID SEQUENCE; ANALYTIC METHOD; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL DAMAGE; CELL METABOLISM; CELL PROTECTION; CONTROLLED STUDY; DOG; DOSE TIME EFFECT RELATION; DRUG TARGETING; HEART INFARCTION; HEART INFARCTION SIZE; HEART INJURY; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE CONTRACTILITY; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; IN VIVO STUDY; METABOLIC DISORDER; MITOCHONDRION; NONHUMAN; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN MODIFICATION; PROTEOMICS; RANDOMIZATION; RECEPTOR BLOCKING; STRESS; TIME; ANIMAL; DRUG EFFECT; GENETICS; HEMODYNAMICS; METABOLISM; PATHOPHYSIOLOGY; REPERFUSION INJURY;

CANIS FAMILIARIS;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; ATP SYNTHETASE COMPLEXES; BIPHENYL COMPOUNDS; CREATINE KINASE; DOGS; HEMODYNAMIC PROCESSES; ISOCITRATE DEHYDROGENASE; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION INJURY; MYOSIN LIGHT CHAINS; PROTEINS; PROTEOMICS; RECEPTOR, ANGIOTENSIN, TYPE 1; TETRAZOLES; VALINE; VENTRICULAR FUNCTION, LEFT;

EID: 16644399501     PISSN: 03008177     EISSN: 15734919     Source Type: Journal    
DOI: 10.1007/s11010-006-9338-9     Document Type: Erratum

References (38)

1. Braunwald E, Kloner RA: The stunned myocardium: prolonged, post-ischemic ventricular dysfunction. Circulation 66: 1146-1149, 1982
2. Ganz P, Ganz W: Coronary blood flow and myocardial ischemia. In: E. Braunwald, D. P. Zipes, P. Libby (eds). Heart Disease 6th edn, Vol 2. Saunders, Philadelphia 2001, pp 1087-1113
3. Jugdutt BI: Effect of reperfusion on ventricular mass, topography and function during healing of anterior infarction. Am J Physiol 272: H1205-H1211, 1997
4. Bolli R: Mechanism of myocardial stunning. Circulation 82: 723-738, 1990
5. Jugdutt BI, Khan MI, Jugdutt SJ, Blinston GE: Impact of left ventricular unloading after late reperfusion of canine anterior myocardial infarction on remodeling and function using isosorbide-5-mononitrate. Circulation 92: 926-934, 1995
6. Jugdutt BI, Schwarz-Michorowski BL, Tymchak WJ, Burton JR: Prompt improvement of left ventricular function and topography with combined reperfusion and intravenous nitroglycerin in acute myocardial infarction. Cardiology 88: 170-179, 1997
7. Armstrong PW, Collen D: Fibrinolysis for acute myocardial infarction: current status and new horizons for pharmacological reperfusion, part 2. Circulation 103: 2987-2992, 2001
8. Yoshiyama M, Kim S, Yamagishi H, Omura T, Tani T, Yanagi S, Toda I, Teragaki M, Akioka K, Takeuchi K, Takeda T: Cardioprotective effect of the angiotensin II type 1 receptor antagonist TCV-116 on ischemia-reperfusion injury. Am Heart J 128: 1-6, 1994
9. Youhua Z, Shouchun X: Increased vulnerability of hypertrophied myocardium to ischemia and reperfusion injury. Relation to cardiac reninangiotensin system. Chin Med J 108: 28-32, 1995
10. 2-receptor activation, bradykinin and Prostaglandins in pigs. J Am Coll Cardiol 32: 1787-1796, 1998
11. E proteins and cGMP. J Cardiovasc Pharmacol Therapeut 5: 301-311, 2000
12. E proteins. J Renin Angiotensin Aldosterone Syst 1: 184-195, 2000
13. 1-receptor blockade after reperfused myocardial infarction. J Renin Angiotensin Aldosterone Syst 2: 134-140, 2001
14. 1 receptor blockade in reperfused myocardial infarction. In: N. S. Dhalla (ed). Signal Transduction and Cardiac Hypertrophy. Kluwer Academic Publishers, Boston, 2002, pp 221-236
15. Arrell DK, Neverova I, Van Eyk JE: Cardiovascular proteomics: Evolution and potential. Circ Res 88: 763-773, 2001
16. 2 receptor expression and blockade after acute ischemia-reperfusion in isolated working rat hearts. Am J Physiol 282: H1206-H1215, 2002
17. Matsumura K, Jeremy RW, Schaper J, Becker LC: Progression of myocardial necrosis during reperfusion of ischemic myocardium. Circulation 97: 795-804, 1998
18. Criscione L, de Gasparo M, Buhlmayer P, Whitebread S, Ramjoue HP, Wood J: Pharmacological profile of valsartan: A potent, orally active, nonpeptide antagonist of the angiotensin II AT1-receptor subtype. Br J Pharmacol 110: 761-771, 1993
19. Culman J, von Heyer C, Piepenburg B, Rascher W, Unger T: Effects of systemic treatment with irbesartan and losartan on central responses to angiotensin II in conscious, normotensive rats. Eur J Pharmacol 367: 255-265; 1999
20. Balghith M, Jugdutt BI: Assessment of diastolic dysfunction after acute myocardial infarction using Doppler echocardiography. Can J Cardiol 18: 69-77, 2001
21. Sawicki G, Dakour J, Morrish DW: Functional proteomics of neurokinin B in the placenta indicates a novel role in regulating cytotrophoblast antioxidant defences. Proteomics 3: 2044-2051, 2003
22. Perkins DN, Pappin DJ, Creasy DM, Cottrell JS: Probability-based protein identification by searching sequence databases using mass spectrometry data. Electrophoresis 20: 3551-3567, 1999
23. Laemmli UK: Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227: 680-685, 1970
24. Moudgil R, Menon V, Xu Y, Musat-Marcu S, Kumar D, Jugdutt BI: Postischemic apoptosis and functional recovery after angiotensin II type 1 receptor blockade in isolated working rat hearts. J Hypertens 19: 1121-1129, 2001
25. McGregor E, Dunn MJ: Proteomics of heart disease. Hum Mol Genet 12: R135-R144, 2003
26. Comte B, Vincent G, Bouchard B, Benderdour M, Des Rosiers C: Reverse flux through cardiac NADP(+)-isocitrate dehydrogenase under normoxia and ischemia. Am J Physiol 283: H1505-H1514, 2002
27. Werrmann JG, Cohen SM: Comparison of effects of angiotensin-converting enzyme inhibition with those of angiotensin II receptor antagonism on functional and metabolic recovery in postischemic working rat heart as studied by [31P] nuclear magnetic resonance. J Cardiovasc Pharmacol 24: 573-586, 1994
28. Van Eyk JE, Powers F, Law W, Larue C, Hodges RS, Solaro RJ: Breakdown and release of myofilament proteins during ischemia and ischemia/reperfusion in rat hearts: Identification of degradation products and effects on the pCa-force relation. Circ Res 82: 261-271, 1998
29. McDonough JL, Arrell DK, Van Eyk JE: Troponin I degradation and covalent complex formation accompanies myocardial ischemia/reperfusion injury. Circ Res 84: 9-20, 1999
30. Yang J, Moravec CS, Sussman MA, DiPaola NR, Fu D, Hawthorn L, Mitchell CA, Young JB, Francis GS, McCarthy PM, Bond M: Decreased SLIM1 expression and increased gelsolin expression in failing human hearts measured by high-density oligonucleotide arrays. Circulation 102: 3046-3052, 2000
31. Rouet-Benzineb P, Bulder JM, Dreyfus P, Delcourt A, Dorent R, Perennec J, Crozatier B, Harf A, Lafuma C: Altered balance between matrix gelatinases (MMP-2 and MMP-9) and their tissue inhibitors in human dilated cardiomyopathy: potential role of MMP-9 in myosin-heavy chain degradation. Eur J Heart Fail 1: 337-352, 1999
32. Reinhardt D, Sigusch HH, Hensse J, Tyagi SC, Korfer R, Figulla HR: Cardiac remodelling in end stage heart failure: Upregulation of matrix metalloproteinase (MMP) irrespective of the underlying disease, and evidence for a direct inhibitory effect of ACE inhibitors on MMP. Heart 88: 525-530, 2002
33. Tyagi SC, Hayden MR, Hall JE: Role of angiotensin in angiogenesis and cardiac fibrosis in heart failure. In: N.S. Dhalla, P. Zahradka, I. Dixon, R. Beamish (eds). Angiotensin II receptor blockade: Physiological and Clinical Implications. Kluwer Academic Publishers, Boston, 1998, pp 537-549
34. 1 receptor blockade upregulates TIMP-3 and improves MMP-9/TIMP-3 balance during in vivo postischemic myocardial reperfusion. (Abstr) Circulation 108: IV-38, 2003
35. Charney RH, Takahashi S, Zhao M, Sonnenblick EH, Eng C: Collagen loss in the stunned myocardium. Circulation 85: 1483-1490, 1992
36. Spinale FG, Mukherjee R, Iannini JP, Whitebread S, Hebbar L, Clair MJ, Melton DM, Cox MH, Thomas PB, de Gasparo M: Modulation of the renin-angiotensin pathway through enzyme inhibition and specific receptor blockade in pacing-induced heart failure: II. Effects on myocyte contractile processes. Circulation 96: 2397-2406, 1997
37. Bolli R, Marban E: Molecular and cellular mechanisms of myocardial stunning. Physiol Rev 79: 609-634, 1999
38. Jugdutt BI: Ventricular remodeling postinfarction and the extracellular collagen matrix. When is enough enough? Circulation 108: 1395-1403, 2003